Shareholders approved all proposed resolutions Paris and Boston, June 5, 2023 - 5:45 pm CEST - Mauna Kea Technologies (Euronext: MKEA)...
Study will advance the validation of Cellvizio® as a real-time biopsy guidance tool during robotic-assisted bronchoscopy Paris and Boston,...
Cash position of €6.7m at May 31, 2023 strengthened by USD 2.5m received from the joint venture with Tasly Pharmaceutical Paris and...
Paris, April 26, 2023 - 5:45 p.m. CEST - At its meeting of April 5, 2023, the Board of Directors of Mauna Kea Technologies (Euronext...
Recognition of first revenues from the Joint Venture with Tasly Pharmaceutical Paris and Boston, April 20, 2023 - 5:45 p.m. CEST - Mauna...
2022 sales in line with expectations at €7.5 million Maintained a stable gross margin at 73% with reduced 2022 operating loss Cash...
Mauna Kea Technologies today announces the coverage of its stock by Portzamparc – Groupe BNP Paribas. Portzamparc – Groupe BNP...
Q4 and full year 2022 in line with expectations at €2.7 million and €7.5 million, respectively U.S. level of sales stable in 2022 at...
Results were published in Respirology and provide further evidence supporting Cellvizio as a key complementary technology to robotic-assisted...
Improvement in gross margin driven by a more favorable sales mix and reduction in operating loss Solid business activity following strategic...
Tasly Mauna Kea Medical Engineering Technology Co. Ltd will expand reach of Cellvizio in China and launch a dedicated platform for neurosurgical...
Dynamic monitoring of the intestinal barrier with Confocal Laser Endomicroscopy demonstrated to be far superior to endoscopic and histologic...
